54,515 Shares in TG Therapeutics, Inc. (NASDAQ:TGTX) Purchased by Artia Global Partners LP

Artia Global Partners LP purchased a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 54,515 shares of the biopharmaceutical company's stock, valued at approximately $1,641,000. TG Therapeutics makes up about 0.6% of Artia Global Partners LP's investment portfolio, making the stock its 23rd largest holding.

Several other hedge funds have also modified their holdings of the company. Bleakley Financial Group LLC bought a new stake in TG Therapeutics during the 4th quarter valued at about $245,000. Castellan Group purchased a new stake in TG Therapeutics during the 4th quarter worth approximately $8,539,000. Barclays PLC grew its position in TG Therapeutics by 83.9% during the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company's stock worth $8,117,000 after purchasing an additional 158,323 shares during the last quarter. JPMorgan Chase & Co. grew its position in TG Therapeutics by 60.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 720,798 shares of the biopharmaceutical company's stock worth $16,859,000 after purchasing an additional 270,286 shares during the last quarter. Finally, Stratos Wealth Advisors LLC purchased a new stake in shares of TG Therapeutics in the 4th quarter valued at $241,000. 58.58% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on TGTX. HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Tuesday, March 4th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $40.67.

TG Therapeutics Price Performance

Shares of TGTX stock traded up $1.65 during mid-day trading on Wednesday, reaching $45.51. The stock had a trading volume of 3,267,648 shares, compared to its average volume of 3,072,435. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market cap of $7.23 billion, a P/E ratio of -455.05 and a beta of 2.14. TG Therapeutics, Inc. has a 12-month low of $14.87 and a 12-month high of $45.88. The business has a 50-day simple moving average of $37.66 and a 200 day simple moving average of $32.81.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. On average, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.